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Abstract
Aim: Tamoxifen (TAM) resistance remains a clinical issue in breast cancer. The authors previously reported 
that 15-hydroxyprostaglandin dehydrogenase (HPGD) was significantly downregulated in tamoxifen-resistant 
(TAMr) breast cancer cell lines. Here, the authors investigated the relationship between HPGD expression, 
TAM resistance and prediction of outcome in breast cancer.
Methods: HPGD overexpression and silencing studies were performed in isogenic TAMr and parental human 
breast cancer cell lines to establish the impact of HPGD expression on TAM resistance. HPGD expression and 
clinical outcome relationships were explored using immunohistochemistry and in silico analysis.
Results: Restoration of HPGD expression and activity sensitised TAMr MCF-7 cells to TAM and 17β-oestradiol, 
whilst HPGD silencing in parental MCF-7 cells reduced TAM sensitivity. TAMr cells released more prostaglandin 
E2 (PGE2) than controls, which was reduced in TAMr cells stably transfected with HPGD. Exogenous PGE2 
signalled through the EP4 receptor to reduce breast cancer cell sensitivity to TAM. Decreased HPGD expression 
was associated with decreased overall survival in ERα-positive breast cancer patients.
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Conclusions: HPGD downregulation in breast cancer is associated with reduced response to TAM therapy via 
PGE2-EP4 signalling and decreases patient survival. The data offer a potential target to develop combination 
therapies that may overcome acquired tamoxifen resistance.
Keywords
Breast cancer, endocrine resistance, 15-hydroxyprostaglandin dehydrogenase, immunohistochemistry, 
survival
Introduction
Due to its ability to bind to and modulate oestrogen receptor alpha (ERα) activity, Tamoxifen (TAM) was the 
first targeted therapy for breast cancer [1], with its widespread use in the clinic now extending to four decades. 
While aromatase inhibitors are now the preferred first line endocrine treatment in the post-menopausal 
setting [2], TAM is favoured in pre-menopausal breast cancer patients [3]. However, approximately 70% of 
patients initially respond to TAM, but most eventually acquire resistance [2]. Acquisition of TAM-resistance 
(TAMr) continues to be a major limitation for long-term management of breast cancer patients. However, the 
mechanism(s) responsible for TAM insensitivity is not yet fully understood.
In the last three decades, various groups have developed cell line models in order to help unravel the 
mechanistic basis of TAMr. Most of these have been achieved through long term culture of the hormone-
sensitive MCF-7 human breast cancer cells in sub-lethal doses of TAM, during which resistant sub-clones 
develop after 3-6 months [4-8]. Using two independently-derived ER positive MCF-7 human breast cancer 
cell models of acquired TAMr developed in our laboratory [9], an Affymetrix® microarray study showed that 
131 genes were upregulated and 156 were downregulated by at least 3-fold, in TAMr MCF-7 cells relative 
to isogenic control cells [10]. One of the genes that were downregulated was 15-hydroxyprostaglandin 
dehydrogenase (HPGD). HPGD (EC 1.1.1.141) is a member of the short-chain alcohol (OH) dehydrogenase 
family and is the key NAD+-dependent enzyme responsible for the biological inactivation of prostaglandins, 
including prostaglandin E2 (PGE2), which is synthesized via the cyclooxygenase (COX) pathway.
Downregulation of HPGD has been shown in several malignancies including lung, colon, bladder, 
endometrial, and gastric cancer and has been shown to have a tumour suppressor roles in some settings 
[11-16]. Studies in breast cancer are contradictory; higher HPGD expression has been reported in ERα-
positive MCF-7 cell with reduced expression in ERα-negative MDA-MB-231 cells, where up-regulation was 
observed following treatment with demethylating agents [17]. In clinically more aggressive primary breast 
cancers, particularly those with a triple negative phenotype, and in breast cancer metastases, HPGD is 
overexpressed, with high HPGD expression associated with poor prognosis and reduced survival [18]. In 
the same study, HPGD silencing induced a mesenchymal-epithelial transition resulting in a less migratory 
phenotype. More recently, data mining from publicly available breast cancer gene expression datasets from 
the Cancer Genome Atlas (TCGA, https://www.cancer.gov/about-nci/organization/ccg/research/structural-
genomics/tcga) and Oncomine (https://www.oncomine.org/), revealed decreased expression of HPGD mRNA 
in breast cancer samples compared with normal, healthy breast tissue [19]. Furthermore, HPGD expression 
was lower still in more aggressive basal/triple negative and HER2-positive breast cancers. Conversely, in 
rare apocrine breast carcinomas, HPGD was highly expressed [20]. Application of a triclustering algorithm, 
δ-TRIMAX to microarray datasets characterized HPGD as one of ten so-called hub-genes associated with 
breast cancer [21], lending support for a role in breast carcinogenesis.
Building on our previous data [10], the aim of this study was to investigate a causal link between HPGD 
expression and function and TAMr, as well as explore the relationship between HPGD expression in breast 
cancer samples and clinical outcomes. The effects of HPGD expression on outcome were examined through 
in silico analysis and by immunohistochemistry in a breast cancer cohort with long term follow up, including 
breast cancer outcomes during adjuvant TAM.
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Materials and methods
Cell lines and culture
The two stable TAMr MCF-7 human breast cancer cell lines have been described previously [9, 10]. All 
MCF-7 isogenic lines were cultured in phenol-red-free RPMI 1640 containing L-glutamine (Invitrogen, UK) 
supplemented with 5% charcoal-stripped steroid-depleted foetal calf serum (FCS; Harlan SeraLab, UK), 
100 U/mL penicillin and 100 U/mL streptomycin and 100 nM 4-hydroxytamoxifen (TAM; Sigma-Aldrich, UK) 
for 12-24 months. Parental cells [termed wild type (WT) MCF-7] were cultured in the same medium, but 
with 0.01% (v/v) ethanol vehicle. Experiments were conducted in phenol-red-free RPMI 1640 supplemented 
with 5% charcoal-stripped steroid-depleted FCS + TAM (0.1-100 nM) or 17β-oestradiol (E2; 0.001-1 nM). 
Bi-monthly mycoplasma checks were consistently negative and annual short tandem repeat (STR) profiling 
confirmed cell provenance, both carried out as a service in Leeds. To minimize genetic drift, cell stocks were 
frozen at low passage and experimental cultures replaced from these stocks every 3-6 months. We also 
studied LCC1, -2 and -9 breast carcinoma cells, which were derived originally in the Clarke laboratory at 
Georgetown, Washington DC and cultured as described [7, 8, 22]. LCC1 cells are estrogen-independent and 
-responsive TAM-sensitive breast cancer cells, which are derived from an estrogen-independent variant of 
MCF-7 cells (MCF7/MIII) through in vivo selection in oophorectomized nude mice (with circulating estrogen 
levels similar to a postmenopausal woman), and subsequently re-cultured in vitro to become a stable cell 
line. LCC2 cells are stable, ER-positive, estrogen-independent, TAM-resistant, and respond to fulvestrant [7]. 
They were derived from the selection of LCC1 for TAM resistance in vitro. LCC9 cells exhibits cross resistance 
to TAM and are unresponsive to fulvestrant [7]. They were derived from the selection of LCC1 for fulvestrant 
resistance in vitro. MCF7:5C and MCF-7:WS8 are oestrogen-independent and dependent, respectively, ER-
positive, progesterone receptor (PR)-negative, and TAM-resistant breast cancer cells [23]. They were derived 
from WT MCF-7 cells following long-term estrogen deprivation (LTED). The main characteristics of the cell 
lines used are detailed in Table 1.
Microarray analysis of LCC1, -2 and -9
Cells were seeded at 300, 000 cells per well in 6-well plates (Corning, UK). They were treated the next day 
with 1 nM E2 for the indicated durations. All experiments were performed in triplicate. Subsequently, cells 
were harvested in TRIzol (Life Technologies, UK) and total RNA was isolated using the Qiagen RNeasy RNA 
purification kit (Qiagen, UK). Isolated RNA (1 µg) was then processed on the Affymetrix Clariom S microarray 
platform (Affymetrix, UK) and used to determine the significance of differential expression of HPGD at 
basal levels.
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay
Metabolic activity was used as a surrogate for cell proliferation, using the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay [9]. Cells were seeded into 96-well plates. After overnight 
attachment, TAM (0.1-100 nM), E2 (0.01-1 µM), PGE2 (1 µM), butaprost or PGE1-OH (both 0.1-1 µM) or ethanol 
vehicle was added. At 96 h post-treatment, cells were incubated with 1 mM MTT for 4 h. The purple formazan 
product was solubilised in propan-1-ol and read at 570 nm using an Opsys MRTM 15 (Dynex Technologies, 
UK). Chemicals were purchased from Sigma-Aldrich (UK) or Cayman Chemical (USA).
Table 1. Characteristics of TAM-resistant breast cancer cell lines derived from MCF-7
Parental cell line                   TAM resistant derivative
Cell line Method of induction of TAM resistance
WT MCF-7
(oestrogen-dependent, TAM-sensitive)
TAMr 1 Chronic TAM exposure (12 months)
TAMr 2 Chronic TAM exposure (21 months)
MCF-7-5C Long-term oestrogen deprivation
MCF-7-WS8 Long-term oestrogen deprivation
MCF-7/LCC1
(oestrogen-independent, endocrine therapy responsive)
LCC2 Stepwise selection against TAM 
LCC9 Stepwise selection against fulvestrant
Explor Target Antitumor Ther. 2020;1:[Online First] | https://doi.org/10.37349/etat.2020.00021 Page 4
Western blot analysis
This was conducted as described previously [24], except that HPGD was detected using a rabbit polyclonal 
antibody (catalogue number NB200-179, Novus Biological, UK, 1:500). Bands were then visualised with 
Supersignal West pico ECL reagent (ThermoFisher, UK).
Real-time polymerase chain reaction (RT-PCR)
Total RNA was extracted, and reverse transcribed as described previously [24]. Real-time polymerase 
chain reaction (RT-PCR) for HPGD or prostaglandin E2 receptor 4 (EP4) mRNA was performed using a SYBR 
Green-based assay (ThermoFisher, UK) on an ABI 7700 sequence detection system using primers for HPGD 
(forward, 5’-TAGTTGGATTCACACGCTCAGC-3’; reverse, 5’-AAAGCCTGGACAAATGGCAT-3’) and EP4 (forward, 
5’-TCTTACTCATTGCCACCTCCCT-3’; reverse, 5’-CTTGGCTGATATAACTGGTTGACG-3’). The ribosomal protein 
gene RPLPO was used as the reference gene (forward, 5’-GAAACTCTGCATTCTCGCTTCC-3’; reverse, 
5’-GATGCAACAGTTGGGTGCCA-3’). Levels of HPGD or EP4 transcripts were quantified using the 2-ΔCt 
method [25].
HPGD transfections
A stab culture of human HPGD cDNA IMAGE clone ID 3638799 was obtained from MRC and HPGD was PCR-
amplified from this using the following primers: forward, 5′-CCGGGATCCTGCACCATGCACGTGAAC-3′; reverse, 
5′-CCCCAAGCTTTCATTGGGTTTTTGCTTG-3′. Products were cloned into pcDNA3.1(-)myc/his (gift from Dr 
Thomas Hughes, University of Leeds). Vectors containing HPGD or empty vector controls were transfected 
into TAMr cells using Lipofectamine 2000 (ThermoFisher, UK). Stable clones were selected and maintained 
in G418 (ThermoFisher, UK)-containing medium (250 µg/mL).
PGE2 ELISA and HPGD enzyme activity assay
Both assays were performed using previously protocols published [26]. For PGE2, serum-free conditioned 
medium was collected from cells after overnight incubation, and PGE2 levels were measured using a 
competitive immunoassay (Amersham Biosciences, UK), and normalised to total cellular protein content as 
measured by Bradford assay. HPGD activity was measured in lysates of WT MCF-7 and TAMr cells by assessing 
the transfer of tritium from 3H-PGE2 to glutamate, catalysed by HPGD and glutamate dehydrogenase [27].
EP4 and HPGD knockdown
Small-interfering (si)-RNAs targeting EP4 or HPGD (ThermoFisher Scientific, UK) were reverse transfected 
into cells using Lipofectamine 2000 according to the manufacturer’s instructions. Briefly, MCF-7 cells were 
mixed with media containing small-interfering RNA (siRNA)/lipid (final siRNA concentration 10 nM) and 
seeded into 96 well plates at 0.4 x 104 cells/well and allowed to establish overnight before incubation with 
drug or vehicle control. Response to treatment was assessed by MTT assay. EP4 or HPGD knockdown was 
assessed by real-time quantitative polymerase chain reaction (qRT-PCR) as described previously [28].
Immunohistochemistry
Following ethical approval (06/Q1206/180) we investigated HPGD expression in 350 primary invasive 
breast cancers, all of which, had been surgically resected and received adjuvant TAM, and were represented 
on tissue microarrays (TMAs) [24, 29]. Out of the 350 cases, 108 cases experienced a relapse (TAMr) and 242 
cases did not [tamoxifen-sensitive (TAMs)]. Mean follow-up was 80 months [range 1-229, standard deviation 
(SD) 44.2]. Tumour staining was achieved using previously described methods [24, 26].
In silico transcriptomic analysis
The relationship between HPGD expression and cancer outcomes was analyzed using Kaplan-Meier Plotter 
(KMplot, https://kmplot.com/analysis/) [30]. Using the 2017 release of the database, a cohort of ERα-
positive breast tumours, previously treated with TAM only and no adjuvant chemotherapy, was analyzed and 
the association between HPGD expression and overall survival (OS). Patients were dichotomized as high or 
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low HPGD expression using lower tertile as a cut-off. Multivariate analysis was done using in-built software 
with Ki67, ER and HER2 as covariates.
In silico analyses for the identification of miRNAs targeting HPGD
We applied miRWalk version 3.0 [31] and TargetScan version 7.2 [32] to a previously described Affymetrix 
miRNA dataset of endocrine sensitive MCF-7:WS8 and resistant MCF-7:5C cells [33] in order to identify 
miRNA-target interactions sites for major HPGD transcripts using default settings. OncoLnc (http://www.
oncolnc.org/) was used to retrieve HPGD and miR-3200-3p expression data from matching breast cancer 
cases in the TCGA database [34]. Kaplan-Meier Plotter [30] was used to investigate the significance of miR-
3200-3p on survival in ERα+ breast cancer treated with any endocrine therapy (not limited to TAM). Cases 
were dichotomised as high or low miR-3200-3p expression using the median expression value as a cut-off.
Statistical analysis
For in vitro analyses, one-way ANOVA was performed. The log rank test was used to compare patient survival 
in the primary breast cancer cohort. Analyses were performed using GraphPad Prism version 7.03 (GraphPad 
Software, La Jolla California, USA). For Affymetrix analyses, ANOVA P-values were calculated using the 
Affymetrix Transcriptome Analysis Console (Affymetrix). The time course plots were plotted as fold-change 
with the baseline value set at 1.
Results
HPGD is downregulated in TAMr MCF-7MMU2 cells
We demonstrated that HPGD was downregulated in two independent TAMr MCF-7 cell lines, which had been 
cultured continuously in 100 nM TAM for 12 (TAMr 1) and 21 (TAMr 2) months [10], respectively by Western 
blot (Figure 1a) and real time PCR (Figure 1b) compared with parental MCF-7 cells. Microarray analysis of 
the independent LCC cell line series and MCF7:5C cells showed that only the oestrogen-independent but 
oestrogen-responsive TAMs cell line LCC1 showed increased expression of HPGD in response to E2 over 
time (Figure 1c).
Effect of HPGD overexpression in MCF-7 TAMr 2 cells
We then explored the effects of introduction of HPGD into MCF-7 TAMr 2 cells. Successful expression of HPGD 
protein following stable transfection was confirmed by Western blotting (Figure 2a). This restored activity of 
HPGD in each of the transfected cell lines to levels like WT MCF-7 (Figure 2a and b). This also sensitized these 
cells to the inhibitory effects of TAM to approximately 60% of the parental MCF-7 cell response (Figure 2c), 
whilst restoring sensitivity to E2 almost completely (Figure 2d).
Modulating the PGE2 axis influences cellular response to TAM
Since HPGD is responsible for the biological inactivation of prostaglandins including PGE2, we tested whether 
increased PGE2 signaling might explain TAMr. We first examined PGE2 levels in serum-free conditioned medium 
collected from MCF-7 and MCF-7 TAMr 2 cells. TAMr cells released higher amounts of PGE2 compared with 
parental MCF-7 cells and this could be reduced to levels approaching that of MCF-7 by HPGD overexpression 
in these cells (Figure 3a). Next, we tested the effect of adding exogenous PGE2 (1 µM) on TAM response in 
two different ERα-positive breast cancer cell lines, MCF-7 and T47D. PGE2 reduced sensitivity of both cell 
lines to TAM (Figure 3b). As PGE2-signalling is mediated by G-protein coupled receptors, we examined if the 
stimulatory EP2 or EP4 receptors might be responsible for mediating the effects of PGE2 on TAM sensitivity. 
We demonstrated that PGE1-OH (an EP4 agonist) was able to mimic the effects PGE2 in decreasing TAM 
sensitivity (Figure 3c; P < 0.015), albeit to a lesser extent than PGE2. However, butaprost (EP2 agonist) had 
no effect at equivalent concentrations (Figure 3d). This suggested that the EP4 receptor might be responsible 
for mediating the effect of PGE2 on TAM sensitivity. Partial silencing of EP4 in WT MCF-7 cells was achieved 
using one siRNA (Figure 3e). EP4 silencing using siRNA 1 inhibited PGE2 induced TAM resistance in these 
cells (Figure 3f).
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Figure 1. HPGD is downregulated in TAMr derivatives of MCF-7 cells. Western blot (a) showing HPGD protein expression in 
WT MCF-7 and its loss in two, independently derived, TAMr MCF-7 cell lines, TAMr 1 and TAMr 2; qRT-PCR (b) shows relative 
expression of HPGD mRNA in these cell lines. Expression was determined using RPLP0 as the reference gene and further 
normalized to baseline at time 0 h (± SD); in (c), expression of HPGD mRNA in LCC1 cells (TAMs) versus LCC2 cells (TAMr), 
LCC9 (TAMr and fulvestrant resistant), and MCF7:5C (TAMr) shows an upregulation over time in LCC1 cells only, with the 
resistant variants remaining largely unchanged during treatment with 1 nM E2
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Figure 2. Effect of overexpressing HPGD in MCF-7 TAMr 2 cells. Western blot (a) showing HPGD expression in stably transfected 
clones of MCF-7 TAMr 2 cells compared to empty vector control and WT MCF-7; in (b), HPGD enzyme activity (cpm/μg protein) 
is restored to levels similar to WT MCF-7 following HPGD-transfection, sensitising cells to inhibitory effects of TAM (* P < 0.05 
vs. MCF-7, Figure 2c) and restoring E2 sensitivity (# P < 0.004 vs. MCF-7, Figure 2d). Data are representative of triplicate 
experiments (± SEM)
Explor Target Antitumor Ther. 2020;1:[Online First] | https://doi.org/10.37349/etat.2020.00021 Page 8
Loss of HPGD expression predicts worse outcomes in breast cancer
We analysed the relationship between HPGD expression and clinical outcome for breast cancer patients 
using the on-line resource Kmplot [30] and from our own cohort of breast cancer patient’s data in separate 
Figure 3. Modulating the PGE2 axis influences cellular response to TAM. (a) Overexpression of HPGD reduced PGE2 production 
in MCF-7 TAMr 2 cells to similar levels to basal production in WT MCF-7 cells; (b) exogenous PGE2 (1 μM, broken lines) reduced 
sensitivity of WT MCF-7 and T47D human breast cancer cells to TAM; (c) PGE1-OH mimicked the effects PGE2 in decreasing TAM 
sensitivity in WT MCF-7 and T47D cells, albeit to a lesser extent; (d) butaprost was ineffective at equivalent concentrations; (e) 
EP4 siRNA1 was selected for effective transient silencing of EP4 expression in WT MCF-7; (f) transient silencing of EP4 reduced 
sensitivity to TAM, only in the presence of PGE2. * denotes P < 0.05; ** denotes P < 0.002; *** denotes P < 0.005 normalised to 
respective vehicle controls
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survival analyses. In the Kmplot cohort, we found that ER+ patients who received adjuvant TAM only and 
had ‘low’ expression of HPGD, had reduced OS by univariate analysis [hazard ratio (HR) = 0.28 (0.13-
0.59), P = 0.0007] (Figure 4a). This remained significant on multivariate analysis (P = 0.001, Figure 4b). 
We then conducted a retrospective immunohistochemical study of HPGD expression in our own cohort of 
breast patients, who all received adjuvant TAM therapy and related HPGD expression to survival. As these 
TMAs have been used extensively in several other studies [24, 29, 35], the number of viable cores that 
could be reliably evaluated was only 144 out of 350 cases. The level of HPGD staining was generally weak to 
moderate (Figure 4c) in positive cases, however cases which completely lacked HPGD were associated with 
worse OS [HR = 0.3 (0.15-0.69), P = 0.047] (Figure 4d), in line with the in silico analysis (Figure 4a). The small 
number of TMA cases available precluded multivariate analysis.
Figure 4. Kaplan-Meier survival analysis of the relationship between HPGD expression and breast cancer outcomes using in silico 
data mining and immunohistochemistry. Using KMplot, HPGD expression was categorised as ‘high’ (red) or ‘low’ (black), with the 
lower tertile expression used as cut-off. (a) Low HPGD expression is associated significantly reduced OS [HR 0.28 (0.13-0.59), 
P = 0.00041] in ERα breast tumours treated with TAM; (b) the association between HPGD expression and OS remained significant 
by multivariate analysis; (c) examples of HPGD staining (brown, DAB staining) in breast cancer tissue sections counterstained 
with haematoxylin (blue), the scale bar indicating 60 µm with some cases lacking any appreciable HPGD (top panels), and others 
showing weak to moderate staining (bottom panel); (d) a retrospective immunohistochemical analysis of HPGD expression in 130 
breast cancers represented on TMAs showed HPGD-negative cases (black) had significantly worse OS [HR = 0.3 (0.15-0.69), 
P = 0.047] compared with HPGD-positive cases (red)
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In silico identification of miRNA-HPGD target interactions
With growing evidence that HPGD is inactivated epigenetically, we sought to identify miRNAs that may 
post-transcriptionally modulate HPGD expression. We interrogated a global miRNA data set established 
in an independent TAM resistance model MCF-7:5C [33]. These TAMr cells were derived from WT MCF-7 
cells (Table 1). In silico analysis revealed numerous miRNAs that were differentially expressed in TAMr 
MCF-7:5C cells compared with TAMs MCF-7:WS8 cells and that are predicted to interact with the three prime 
untranslated region (3'-UTR) of the HPGD transcripts (Table 2).
Table 2. In silico prediction of miRNAs differentially expressed in TAMr MCF-7:5C vs. TAMs MCF-7:WS8 that are predicted to 
interact with 3’UTR of major HPGD transcripts
miRNA Fold change Ensembl ida Binding 
probabilityb
Longest consecutive 
pairingsb
hsa-miR-432-5p 105.24 ENST00000504433 0.85 7
hsa-miR-382-5p 54.71 ENST00000296521, ENST00000542498 0.85 9
hsa-miR-487a-3pc 42.78 ENST00000296522.6 - -
hsa-miR-31-5p 28.67 ENST00000296522, ENST00000296521, 
ENST00000422112,
ENST00000510901, ENST00000541923, 
ENST00000542498
1.0 14
hsa-miR-543 19.49 ENST00000296522, ENST00000296521, 
ENST00000422112,
ENST00000541923, ENST00000542498/
ENST00000510901
0.85/0.92 17
hsa-miR-493-3p 13.35 ENST00000296522, ENST00000296521, 
ENST00000422112,
ENST00000541923, ENST00000542498/
ENST00000510901
0.85/0.88 19
hsa-miR-376c-3pc 10.65 ENST00000296522.6 - -
hsa-miR-337-5p 6.46 ENST00000296522, ENST00000296521, 
ENST00000422112,
ENST00000541923, ENST00000542498/
ENST00000510901
0.85/0.92 7
hsa-miR-505-5p 6.32 ENST00000296522, ENST00000422112, 
ENST00000504433,
ENST00000510901/ENST00000541923
1.0/0.85 6
hsa-miR-1972 5.64 ENST00000504433 0.92 7
hsa-miR-410-3pc 4.00 ENST00000296522.6 - -
hsa-miR-154-5p 3.39 ENST00000504433 0.85 5
hsa-miR-485-5p 3.08 ENST00000296522, ENST00000296521, 
ENST00000422112,
ENST00000510901, ENST00000541923, 
ENST00000542498
1.0 7
hsa-miR-199a-3pc 2.91 ENST00000296522.6 - -
hsa-miR-654-3pc 2.89 ENST00000296522.6 - -
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We then tested the association between each of the listed miRNAs and HPGD mRNA levels in 987 breast 
cancer samples from the TCGA database using OncoLnc [34] where both miRNA and mRNA expression data 
were available. Only one miRNA, namely miR-3200-3p, had an inverse relationship between its expression 
levels and HPGD mRNA levels in this dataset (Spearman, ρ = -0.25, P < 0.0001). We used the Kmplot online 
resource [30] to analyse the association between miR-3200-3p expression and OS in ER+ breast cancer 
patients treated with any endocrine therapy, irrespective of grade, molecular subtype, and lymph node status. 
High miR-3200-3p expression was associated with significantly reduced OS (Figure 5a) and a weak negative 
correlation (R2 = 0.25) was observed between miR-3200-3p and HPGD (Figure 5b) using data from TCGA 
analysed using the OncoLnc platform [34].
Table 2. In silico prediction of miRNAs differentially expressed in TAMr MCF-7:5C vs. TAMs MCF-7:WS8 that are predicted to 
interact with 3’UTR of major HPGD transcripts (continued)
miRNA Fold change Ensembl ida Binding 
probabilityb
Longest consecutive 
pairingsb
hsa-miR-493-5p 2.68 ENST00000296522, ENST00000296521, 
ENST00000422112,
ENST00000542498
0.85 10
hsa-miR-381-3p 2.66 ENST00000510901 0.85 8
hsa-miR-330-3p 2.54 ENST00000504433/ENST00000510901/
ENST00000542498
0.92/0.85/1 9/7/7
hsa-miR-154-3pc 2.35 ENST00000296522.6 - -
hsa-miR-30a-3p 1.88 ENST00000504433 0.92/0.85 10/8
hsa-miR-4298 1.83 ENST00000296522, ENST00000296521, 
ENST00000422112,
ENST00000510901, ENST00000541923, 
ENST00000542498
1.0 8
hsa-miR-3200-3pc 1.82 ENST00000296522.6 - -
hsa-miR-106a-5pc 1.75 ENST00000296522.6 - -
hsa-miR-20b-5pc 1.74 ENST00000296522.6 - -
hsa-miR-425-5pc 1.71 ENST00000296522.6 - -
hsa-miR-17-5p 1.69 ENST00000504433 0.85 10
hsa-miR-500a-5p 1.66 ENST00000296522, ENST00000296521, 
ENST00000422112,
ENST00000541923, ENST00000542498, 
ENST00000510901
0.92 8
hsa-miR-1293 1.60 ENST00000296522, ENST00000296521, 
ENST00000422112,
ENST00000541923, ENST00000542498, 
ENST00000510901
1.0 9
hsa-miR-20a-5p 1.56 ENST00000504433 0.92 10
Listed are miRNAs with fold change > 1.5; miRNAs underlined refer to the DLK-DIO3 locus on chromosome 14; miRWalk 
3.0 [31] and TargetScan 7.2 [32] tools have been used to identify miRNA-target interactions; a major targeted transcripts are 
listed with respective Ensembl id; b binding probability and longest consecutive pairings are listed according to miRWalk 3.0 
predictions; c additional miRNAs predicted only with TargetScan 7.2 tool (on most prevalent ENST00000296522.6 transcript)
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Discussion
We have demonstrated a downregulation of HPGD expression in TAM-resistant breast cancer both in vitro 
in multiple series of TAMs and TAMr isogenic cell line pairs and in clinical samples using retrospective 
immunohistochemistry studies and in silico approaches. We have also shown that TAM resistance is associated 
with PGE2 signalling via the EP4 receptor in vitro.
Figure 5. Relationship between HPGD and miR-3200-3p expression in breast cancer. Using KMplot, miR-3200-3p expression was 
categorized as high or low, with median expression used as cut-off. Kaplan-Meier survival analysis demonstrated a statistically 
significant effect of miR-3200-3p on the OS of ERα-positive breast cancer patients treated with any endocrine therapy (a); 
correlation analysis of matched gene expression levels of HPGD and miR-3200-3p in 987 breast cancer cases obtained from the 
TCGA revealed a weak negative correlation [R2 = 0.25; (b)]
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A key role of HPGD is to inactivate PGE2. Having confirmed its downregulation in TAMr cells using various 
experimental approaches and in different cell lineages, we showed that stable transfection of human HPGD 
into MCF-7 TAMr 2MCF-7 cells restored HPGD enzyme activity, at the same time significantly sensitising these 
cells to TAM, and suggesting a functional role of HPGD downregulation in acquired TAMr. Our hypothesis that 
HPGD mediated its effects via this axis was strengthened by the observation that treatment of 2 different 
ER+ TAM-sensitive cell lines with exogenous PGE2 increased the resistance of both cell lines to the growth-
inhibitory effects of TAM.
PGE2 exerts its effects through binding to cell surface G-protein coupled EP receptors. Four subtypes 
have been identified, EP1, -2, -3 and -4, with each coupled to different intracellular signalling pathways. All 
are stimulatory except for EP3, which exerts inhibitory effects. We used a pharmacological approach to target 
EP2 and EP4, treating parental MCF-7 and T47D cells with PGE1-OH (EP4 receptor agonist) or with butaprost 
(EP2 receptor agonist). PGE1-OH was able to mimic the effects of PGE2 (albeit to a lesser extent), whereas 
butaprost had no effect at equivalent concentrations. We suggest that the EP4 receptor is responsible for 
mediating the TAMr effect of PGE2. While our knockdown experiment implied a role for EP4, we were only 
able to achieve partial knockdown with a single siRNA, which limits the conclusions from our data. Consistent 
with our data, a study has shown that EP4 gene expression was upregulated in TAMr MCF-7 cells, also 
generated from long term oestrogen deprivation, and in patients resistant to aromatase inhibitor therapy. 
Furthermore, the exposure to two separate EP4-specific antagonists, GW627368X and ONO-AE3-208, 
decreased estrogen-independent cell growth in LTED MCF-7 cells [36]. These authors proposed a molecular 
mechanism by which EP4 signalling may drive ligand-independent ERα activation by driving the binding of 
the coactivator-associated arginine methyltransferase 1 (CARM1), an ERα co-factor, to the receptor, leading 
to its activated status [36].
There is evidence that HPGD is post-transcriptionally regulated via miRNAs, with miR-21 identified as 
targeting HPGD in oral tongue squamous cell carcinoma [37]. Silencing of miR-21 expression in human breast 
cancer cell lines has been shown to increase TAM sensitivity [38]. miR-21 was found to be overexpressed 
in TAMr cell line compared to TAMs cell lines [39], which may contribute to HPGD downregulation in TAM 
resistant breast cancer. However, miR-21 was not identified as differentially expressed in TAMr MCF-7:5C 
cells compared with TAMs MCF-7:WS8 cells. We identified several differentially expressed miRNAs predicted 
to interact with the 3’UTR of HPGD transcripts. Of these, miR-3200-3p expression was found to be inversely 
correlated with HPGD mRNA level, suggesting a possible role of miR-3200-3p in the regulation of HPGD 
expression. Using an in silico approach we found that increased miR-3200-3p levels were significantly 
associated with decreased OS in ER positive breast cancer patients treated with endocrine therapy. There are 
no data available thus far establishing a direct interaction between miR-3200-3p and HPGD mRNA, however 
correlation between HPGD and miR-3200-3p in breast cancer cases in the TCGA database using the OncoLnc 
platform [34] revealed a weak negative correlation. A key next step would be to validate that the 3'-UTR of 
HPGD is a target of miR-3200-3p in a luciferase reporter assay in vitro, with in vivo validation also warranted. 
Interestingly, while this work was under review, miR-3200-3p was identified using data from TCGA as a 
so-called miRNA master regulator (MMR) in breast cancer and was one of 61 MMRs which displayed high 
oncogenic activity [40].
The immunohistochemistry on human breast cancer samples and the in silico analysis demonstrated 
that reduced expression of HPGD was associated with worse patient outcomes, consistent with a study 
demonstrating that low levels of HPGD predicted reduced recurrence free survival and OS in a cohort of breast 
cancer patients, split into normal weight, overweight and obese groups, in which few received endocrine 
therapy (15%) [41]. In our study, all cases received adjuvant TAM, with HPGD downregulation associated 
with reduced response to endocrine treatment and worse clinical outcomes.
Some studies of HPGD expression in breast tissues have demonstrated higher expression in normal breast 
tissue than breast cancer [19], supporting a tumour suppressive role [17, 42]. However, this is an inconsistent 
finding. One study showed that high, rather than low, HPGD expression was significantly associated with 
poor outcome in triple negative breast cancer [18]. However, tumours lacking expression of either ERα, PR 
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and HER2 are recognised to have worse prognosis. Our cohort was predominantly ER-positive (77%) and 
the in silico analysis was restricted to ER-positive cases only. Such context-dependency has been supported 
through a data mining approach where HPGD expression was found to be differentially expressed across 
the various molecular subtypes of breast cancer [19]. However, in this study [19], HPGD expression was 
significantly decreased in triple negative breast cancer compared to other molecular subtypes.
Data extrapolated from clinical trials is beginning to indicate that the risk of breast cancer relapse is 
reduced by extending time on endocrine therapy from 5 to 10 years [43]. While this is good for patient 
outcome, there will likely be a lag period before these benefits are seen in the clinic. Understanding the 
mechanisms which underline endocrine therapy resistance remains an important biological question. This 
study demonstrated that HPGD downregulation in ER-positive breast cancer is associated with reduced 
response to adjuvant TAM therapy via PGE2-EP4 signalling and decreased patient survival. These data offer a 
potential target to develop combination therapies that may overcome TAM acquired resistance.
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